IB
InSitu Biologics
United States · Biotech
Biotechnology company developing localized, sustained-release drug delivery, with INSB200 as its lead candidate for post-surgical pain management.
Product
InSitu Biologics is developing a drug-delivery platform designed to retain a therapy near an injection site and release it over several days. Its lead candidate, INSB200, targets post-surgical pain through a peripheral nerve-block injection.
The company is pursuing a non-opioid approach intended to extend localized pain relief while limiting systemic exposure. It plans an investigational new drug submission in the first quarter of 2027 and a Phase 1/2 trial in the second quarter, making clinical development the next step for the candidate.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Convertible note financing | $1.3M | Participants not disclosed |